I have put my very life in the hands of the company providing me PD support, Fresenius Medical Care, ticker symbol FMS. They provide Liberty Cycler equipment, medical support personnel, disposables, monthly supply replenishment, labs, and online support. Quite a mouthful. Given the level of my dependence on FMS, it behooves me to know all that is relevant about this company.
Wiki offers the following insights: Fresenius Medical Care AG & Co. KGaA is a German healthcare company that provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives (When on hemodialysis – I am on Peritoneal dialysis every night.)
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group’s revenue.
The company is on the Best Employers List published by Forbes. (Note: Fresenius is #339 on Forbes’s Global 2000 in 2022.)
In December 2022 Helen Giza (54) was appointed Chief Executive Officer of FMS. Helen Giza joined Fresenius Medical Care in 2019 as Chief Financial Officer and took on the additional roles of Deputy CEO and Chief Transformation Officer in 2022 heading the FME25 transformation program. Previously, she was Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals since 2018. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of Takeda’s U.S. business unit since 2008. Prior to that, she held a number of key international finance and controlling positions, amongst others at TAP Pharmaceuticals and Abbott Laboratories. Helen Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, USA. From here:
Graphical analysis of FMS from a stock perspective from here is below:
On 1/20/2023 I bought 500 shares of FMS at $18.26 per share. Today, 1/24/2023 I am down $.20 per share. They have plenty of room to run (I hope!)
Leave a Reply